ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 139 for:    "Measles"

Long-term Follow-up of Measles Antibodies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00168571
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : September 22, 2011
Sponsor:
Collaborators:
Danish Council for Development Research
Novo Nordisk A/S
Fonden til Lægevidenskabens Fremme
Medical Research Council Unit, The Gambia
Information provided by:
Bandim Health Project

Brief Summary:
Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would be the first to describe the persistence of measles antibodies after two doses of measles vaccine, and the study would allow us to identify unprotected children and offer them revaccination. Since persistence of measles antibodies is of crucial importance to measles control, the study will contribute significantly to the existing knowledge and might have important implications for future eradication programmes.

Condition or disease Intervention/treatment Phase
Measles Biological: Measles vaccine Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Enrollment : 1960 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau
Study Start Date : March 2002
Actual Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Measles
U.S. FDA Resources




Primary Outcome Measures :
  1. Measles antibody level


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: Children participating in the Two-dose trial (Non-Specific Effects of Standard Titre Measles Vaccination, Protocol ID: IC18-CT95-0011-Twodose1)

Exclusion Criteria: Severe illness requiring hospitalisation


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168571


Locations
Guinea-Bissau
Bandim Health Project
Bissau, Apartado 861, Guinea-Bissau, 1004 Bissau Codex
Sponsors and Collaborators
Bandim Health Project
Danish Council for Development Research
Novo Nordisk A/S
Fonden til Lægevidenskabens Fremme
Medical Research Council Unit, The Gambia
Investigators
Study Director: PETER AABY, MSc, Dr Med Bandim Health Project
Principal Investigator: MAY-LILL GARLY, PHD, DTM&H Bandim Health Project

Additional Information:
ClinicalTrials.gov Identifier: NCT00168571     History of Changes
Other Study ID Numbers: LTAB-2288/2292-Twodose1
NOVO-2288
Lægevidenskabens Fremme-2292
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 22, 2011
Last Verified: September 2006

Keywords provided by Bandim Health Project:
Measles vaccine
Measles
Measles antibodies
Immunisation
Low income country
Guinea-Bissau
Bandim Health Project
Measles antibody level

Additional relevant MeSH terms:
Measles
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases
Vaccines
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs